Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022

Rhea-AI Summary

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) has announced that it will report its financial results for the fourth quarter and full year 2021 on February 15, 2022, following market close. The company will hold a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. A live audio webcast will be available on its website, with a replay accessible within 24 hours post-event.

Adaptive is focused on the adaptive immune system, developing diagnostic and therapeutic products. They have three commercial products and a strong clinical pipeline aimed at various diseases.

Positive

• Strong focus on the adaptive immune system with a commercial-stage biotechnology approach.
• Three commercial products and a robust clinical pipeline targeting cancer, autoimmune, and infectious diseases.

Negative

• None.

SEATTLE, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, February 15, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.        

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Laura Cooper
205-908-5603
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies report its fourth quarter and full year 2021 financial results?

Adaptive Biotechnologies will report its financial results on February 15, 2022.

What time is the conference call for Adaptive Biotechnologies' financial results?

The conference call will be held at 1:30 PM PT / 4:30 PM ET.

Where can I listen to the financial results webcast for ADPT?

The webcast will be available on the Investors section of Adaptive's website.

What is Adaptive Biotechnologies focused on?

Adaptive Biotechnologies is focused on harnessing the adaptive immune system for diagnostics and therapies.

What types of diseases does Adaptive Biotechnologies target?

Adaptive targets cancer, autoimmune conditions, and infectious diseases.